Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL747 in Subjects With Alzheimer's Disease

Trial Profile

A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL747 in Subjects With Alzheimer's Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2019

At a glance

  • Drugs DNL-747 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Denali Therapeutics Inc
  • Most Recent Events

    • 27 Nov 2018 Status changed from planning to recruiting.
    • 11 Nov 2018 New trial record
    • 01 Nov 2018 According to a Denali Therapeutics media release, this trial is expected to commence in the near-term and Denali will be responsible clinical development costs for this phase Ib study of DNL747 in Alzheimers disease.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top